Sildenafil Citrate Tablet, Film Coated
Product Images NDC 72888-018

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72888-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Principal Display Panel (20 mg Tablet Bottle Label)
This is a medication description for Sildenafil tablets. Each tablet contains 20mg of Sildenafil citrate USP. The usual dosage information can be found on the prescribing information. The tablets should be stored at controlled room temperature and dispensed in a tight container. The medication is only for adult use and should be kept out of the reach of children. More patient information can be found on the website. This is a prescription medication with 1,000 tablets per container. It is distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited in India.*
FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Principal Display Panel (20 mg Tablet Bottle Label)
Each tablet of the medicine contains 20 mg sildenafil citrate USP. The patient information sheet is available on the website mentioned. Look at the accompanying prescribing information for the usual dosage. The medicine is distributed by Advagen Pharma Ltd. It should be stored below 25°C and away from children's reach. The medicine is manufactured by Rubicon Research Private Limited, Ambernath, India. The details regarding the manufacturing license number are also given. However, it is not clear what the overprinting area is.*
FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

Graph (Sildenafil Tablets Usp 20mg Figure 07)
This text provides recommendations for nodose adjustment of various drugs, such as Acitomycin, Bosentan, Cimetidines, Evomyeint, Maslox, Oral Contraceptives, Sapionis, along with their respective AUC and Cmax values. The text also mentions the interaction of drug fold change and 90% CI recommendations. Additionally, there is a reference made to change relative to Sildenafil alone, with a vertical solid line indicating 1. The text also mentions that there is no benefit on exercise capacity when Sildenafil is added to Bosentan therapy.*
FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

Graph (Sildenafil Tablets Usp 20mg Figure 08)
This is a drug interaction table showing the interaction of Acenocoumarol with other drugs such as Aspirin, Atorvastatin, Bosentan, Ethinyloestradiol, among others. The table provides recommendations for the fold changes and 90% CI for INR AUC, Cmax, and BT. It also indicates when co-administration is not recommended, such as the case of ritonavir with sildenafil PK. The table also shows that sildenafil has no benefit on exercise capacity when added to bosentan therapy.*
FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

Graph (Sildenafil Tablets Usp 20mg Figure 09)
This is a table showing the change from baseline (in meters) for different doses of Sildenafil (a medication used to treat erectile dysfunction) in a 12-week study. The doses were placebo, 20mg TID, 40mg TID, and 80mg TID. The results were measured at weeks 4, 8, and 12.*
FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

Graph (Sildenafil Tablets Usp 20mg Figure 10)
This appears to be a medical report assessing the effectiveness of Sildenafil (also known as Sidenafi) for treating Idiopathic Pulmonary Arterial Hypertension (IPAH). The report includes data on the patients' baseline walk distance, age, gender, and mean PAP (pulmonary artery pressure) before and after treatment with Sildenafil. The main measure of treatment effectiveness appears to be the change in 6-minute walk distance after treatment, which is graphed at the end of the report.*
FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.